

Rehap Investigators

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5573600/publications.pdf>

Version: 2024-02-01

183
papers

3,584
citations

236912

25
h-index

161844

54
g-index

207
all docs

207
docs citations

207
times ranked

3489
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D51-D59.	2.8	432
2	Survival in pulmonary hypertension in Spain: insights from the Spanish registry. <i>European Respiratory Journal</i> , 2012, 40, 596-603.	6.7	342
3	Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. <i>European Journal of Heart Failure</i> , 2005, 7, 1011-1016.	7.1	246
4	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2021, 384, 1204-1215.	27.0	224
5	Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. <i>European Heart Journal</i> , 2018, 39, 1255-1264.	2.2	166
6	Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 523-533.	7.1	113
7	Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 942-948.	0.6	102
8	Pulmonary hypertension and congenital heart disease: An insight from the REHAP National Registry. <i>International Journal of Cardiology</i> , 2015, 184, 717-723.	1.7	80
9	Extracorporeal Membrane Oxygenation as a Bridge to Emergency Heart-Lung Transplantation in a Patient With Idiopathic Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 466-468.	0.6	78
10	Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial. <i>International Journal of Cardiology</i> , 2017, 231, 277-283.	1.7	76
11	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. <i>American Heart Journal</i> , 2014, 167, 210-217.	2.7	59
12	A founder <i>EIF2AK4</i> mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. <i>Clinical Genetics</i> , 2015, 88, 579-583.	2.0	57
13	The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 491-503.	2.5	55
14	Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective. <i>International Journal of Cardiology</i> , 2016, 203, 938-944.	1.7	46
15	Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. <i>European Journal of Heart Failure</i> , 2004, 6, 615-617.	7.1	42
16	COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. <i>ERJ Open Research</i> , 2020, 6, 00520-2020.	2.6	40
17	Calidad de vida relacionada con la salud en una cohorte nacional de pacientes con hipertensi3n arterial pulmonar o hipertensi3n pulmonar tromboemb3lica cr3nica. <i>Archivos De Bronconeumologia</i> , 2013, 49, 181-188.	0.8	38
18	Comparison of Baseline Characteristics and Survival Between Patients With Idiopathic and Connective Tissue Disease-related Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 621-627.	0.6	37

#	ARTICLE	IF	CITATIONS
19	Sacubitril/valsartan eligibility and outcomes in the ESC/EORP/HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	7.1	35
20	Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension. <i>Journal of Physiology</i> , 2019, 597, 1087-1101.	2.9	35
21	Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. <i>European Respiratory Journal</i> , 2019, 54, 1901030.	6.7	33
22	Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. <i>Archivos De Bronconeumologia</i> , 2018, 54, 205-215.	0.8	30
23	Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry. <i>Internal Medicine Journal</i> , 2021, 51, 355-365.	0.8	30
24	Estándares asistenciales en hipertensión pulmonar. <i>Revista Espanola De Cardiologia</i> , 2008, 61, 170-184.	1.2	26
25	Guía de diagnóstico y tratamiento de la hipertensión pulmonar: resumen de recomendaciones. <i>Archivos De Bronconeumologia</i> , 2018, 54, 205-215.	0.8	26
26	Molecular Analysis of BMPR2 , TBX4 , and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 1011-1019.	0.6	25
27	Giant pulmonary artery aneurysm in a patient with vasoreactive pulmonary hypertension: a case report. <i>BMC Cardiovascular Disorders</i> , 2011, 11, 64.	1.7	24
28	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.	2.9	23
29	Evaluación diagnóstica y pronóstica actual de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 583-596.	1.2	21
30	Alta incidencia de bacteriemia por bacilos gramnegativos en pacientes con hipertensión pulmonar tratados con treprostnil por vía intravenosa. <i>Archivos De Bronconeumologia</i> , 2012, 48, 443-447.	0.8	21
31	Angioplastia pulmonar con balón en la hipertensión pulmonar tromboembólica crónica no operable. Experiencia inicial en España en una serie de 7 pacientes. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 535-537.	1.2	21
32	Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. <i>Diagnostics</i> , 2020, 10, 548.	2.6	21
33	Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4. <i>PLoS ONE</i> , 2020, 15, e0232216.	2.5	21
34	Customized Massive Parallel Sequencing Panel for Diagnosis of Pulmonary Arterial Hypertension. <i>Genes</i> , 2020, 11, 1158.	2.4	21
35	Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). <i>Pulmonary Circulation</i> , 2019, 9, 1-3.	1.7	20
36	Control clínico en la EPOC: ¿un nuevo objetivo terapéutico?. <i>Archivos De Bronconeumologia</i> , 2020, 56, 68-69.	0.8	20

#	ARTICLE	IF	CITATIONS
37	Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2020, 9, 448.	2.4	20
38	Effect of Different Pharmacologic Agents to Reverse Severe Pulmonary Hypertension Among End-Stage Heart Failure Patients. <i>Transplantation Proceedings</i> , 2009, 41, 2477-2479.	0.6	19
39	Physical activity levels are low in patients with pulmonary hypertension. <i>Annals of Translational Medicine</i> , 2018, 6, 205-205.	1.7	19
40	Characterization of rare ABCC8 variants identified in Spanish pulmonary arterial hypertension patients. <i>Scientific Reports</i> , 2020, 10, 15135.	3.3	19
41	Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-Term Survival. <i>Journal of the American Heart Association</i> , 2021, 10, e019949.	3.7	18
42	Pulmonary arterial hypertension related to human immunodeficiency virus infection: A case series. <i>World Journal of Cardiology</i> , 2014, 6, 495.	1.5	18
43	Novel Genetic and Molecular Pathways in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease. <i>Cells</i> , 2021, 10, 1488.	4.1	17
44	Tromboendarterectomía pulmonar en 106 pacientes con hipertensión pulmonar tromboembólica crónica. <i>Archivos De Bronconeumología</i> , 2015, 51, 502-508.	0.8	15
45	Clinical course of COVID-19 in pulmonary arterial hypertension patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 775-778.	0.6	15
46	Compression of the Left Main Coronary Artery by a Giant Pulmonary Artery Aneurysm. <i>Circulation</i> , 2013, 127, 1340-1341.	1.6	14
47	Balloon Pulmonary Angioplasty for Inoperable Patients With Chronic Thromboembolic Pulmonary Hypertension. Observational Study in a Referral Unit. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 224-232.	0.6	14
48	Frequency, Predictors, and Prognostic Impact of Pulmonary Artery Aneurysms in Patients With Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2019, 123, 474-481.	1.6	14
49	Vitamin D deficiency among patients with pulmonary hypertension. <i>BMC Pulmonary Medicine</i> , 2019, 19, 258.	2.0	13
50	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 177, 106241.	2.9	13
51	Novel TNIP2 and TRAF2 Variants Are Implicated in the Pathogenesis of Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2021, 8, 625763.	2.6	13
52	Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008166.	3.9	13
53	Lung Transplantation in Pulmonary Hypertension: A Multidisciplinary Unit's Management Experience. <i>Transplantation Proceedings</i> , 2018, 50, 1496-1503.	0.6	12
54	Expanding the Evidence of a Semi-Dominant Inheritance in GDF2 Associated with Pulmonary Arterial Hypertension. <i>Cells</i> , 2021, 10, 3178.	4.1	12

#	ARTICLE	IF	CITATIONS
55	Complicaciones de los aneurismas proximales de arteria pulmonar en pacientes con hipertensi3n pulmonar severa. Revista Espanola De Cardiologia, 2010, 63, 617-618.	1.2	11
56	Lung and heart-lung transplantation in pulmonary arterial hypertension. PLoS ONE, 2017, 12, e0187811.	2.5	11
57	Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. International Journal of Cardiology, 2019, 275, 158-164.	1.7	11
58	PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. Orphanet Journal of Rare Diseases, 2021, 16, 196.	2.7	11
59	Hipertensi3n arterial pulmonar. Medicina Cl3nica, 2022, 158, 622-629.	0.6	11
60	Balloon Pulmonary Angioplasty for Inoperable Patients With Chronic Thromboembolic Pulmonary Hypertension. Preliminary Experience in Spain in a Series of 7 Patients. Revista Espanola De Cardiologia (English Ed), 2015, 68, 535-537.	0.6	10
61	Pulmonary Thromboendarterectomy in 106 Patients With Chronic Thromboembolic Pulmonary Hypertension. Archivos De Bronconeumologia, 2015, 51, 502-508.	0.8	10
62	Enfermedad venooclusiva pulmonar y hemangiomas capilar pulmonar. Medicina Cl3nica, 2017, 148, 265-270.	0.6	10
63	Induction treatment with monoclonal antibodies for heart transplantation. Transplantation Reviews, 2011, 25, 21-26.	2.9	9
64	Hipertensi3n pulmonar tromboemb3lica cr3nica en Espa3a: una Ad3cada de cambio. Revista Espanola De Cardiologia, 2021, 74, 384-392.	1.2	9
65	Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy. Transplantation Proceedings, 1999, 31, 2515-2516.	0.6	8
66	Current Diagnostic and Prognostic Assessment of Pulmonary Hypertension. Revista Espanola De Cardiologia (English Ed), 2010, 63, 583-596.	0.6	8
67	Evaluation of a nurse-led intervention program in heart failure: A randomized trial. Medicina Cl3nica, 2019, 152, 431-437.	0.6	8
68	An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, e12024.	1.7	8
69	Steroid withdrawal in nonimmunologically selected heart transplant recipients. Transplantation Proceedings, 2002, 34, 164-165.	0.6	7
70	Trends in Pulmonary Hypertension Over a Period of 30 Years: Experience From a Single Referral Centre. Revista Espanola De Cardiologia (English Ed), 2017, 70, 915-923.	0.6	7
71	Resultados de la tromboendarterectom3a pulmonar en la hipertensi3n pulmonar tromboemb3lica cr3nica. Medicina Cl3nica, 2017, 149, 1-8.	0.6	7
72	2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. Seminars in Arthritis and Rheumatism, 2018, 47, 870-876.	3.4	7

#	ARTICLE	IF	CITATIONS
73	Potential Molecular Pathways Related to Pulmonary Artery Aneurysm Development: Lessons to Learn from the Aorta. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2509.	4.1	7
74	Tratamiento de la hipertensi3n pulmonar asociada a la infecci3n por VIH con treprostinil. <i>Revista Espanola De Cardiologia</i> , 2003, 56, 421-425.	1.2	7
75	Efficacy of Oral Sildenafil as Rescue Therapy in Patients With Severe Pulmonary Arterial Hypertension Chronically Treated With Prostacyclin. Long-Term Results. <i>Revista Espanola De Cardiologia (English)</i> Tj ETQq1 1 0.78.4314 rgBT /Overl	1.0	7
76	Steroid Withdrawal During 5 Years Following Heart Transplantation, and the Relationship Between Steroid Dosage at 1-Year Follow-up and Complications During the Next 2 Years: Results From the RESTCO Study. <i>Transplantation Proceedings</i> , 2012, 44, 2631-2634.	0.6	6
77	Predictive value of NT-proBNP combined with exercise capacity variables in pulmonary artery disease: Insights from a Spanish cohort. <i>International Journal of Cardiology</i> , 2015, 186, 32-34.	1.7	6
78	Rationale and Design of a Randomized Controlled Trial Evaluating Whole Muscle Exercise Training Effects in Outpatients with Pulmonary Arterial Hypertension (WHOLEi+12). <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 543-550.	2.6	6
79	Management of incidentally diagnosed pulmonary artery dissection in patients with pulmonary arterial hypertension. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 210-212.	1.4	6
80	Unexpected Favourable Course of Coronavirus Disease 2019 in Chronic Thromboembolic Pulmonary Hypertension Patients. <i>Archivos De Bronconeumologia</i> , 2020, 56, 749-752.	0.8	6
81	Clinical relevance of adding intravascular ultrasound to coronary angiography for the diagnosis of extrinsic left main coronary artery compression by a pulmonary artery aneurysm in pulmonary hypertension. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 691-700.	1.7	6
82	Chronic thromboembolic pulmonary hypertension in Spain: a decade of change. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 384-392.	0.6	6
83	Radiological Findings in Multidetector Computed Tomography (MDCT) of Hereditary and Sporadic Pulmonary Venous Occlusive Disease: Certainties and Uncertainties. <i>Diagnostics</i> , 2021, 11, 141.	2.6	6
84	Pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension: the Spanish experience. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 151-160.	1.7	6
85	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. <i>Scientific Reports</i> , 2022, 12, 5289.	3.3	6
86	Complications of Proximal Pulmonary Artery Aneurysms in Patients With Severe Pulmonary Arterial Hypertension. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 617-618.	0.6	5
87	Predictors of Pulmonary Hypertension in Patients With End-stage Heart Failure. <i>Congestive Heart Failure</i> , 2012, 18, 212-216.	2.0	5
88	Use of Atrial Septostomy to Treat Severe Pulmonary Arterial Hypertension in Adults. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 78-81.	0.6	5
89	Effects of an 8-month exercise intervention on physical capacity, NT-proBNP, physical activity levels and quality of life data in patients with pulmonary arterial hypertension by NYHA class. <i>Data in Brief</i> , 2017, 12, 37-41.	1.0	5
90	Variable Expressivity of a Founder Mutation in the EIF2AK4 Gene in Hereditary Pulmonary Venous Occlusive Disease and Its Impact on Survival. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 86-94.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Letter by Hernandez-Gonzalez et al Regarding Article, "Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension". <i>Circulation</i> , 2018, 137, 2411-2412.	1.6	5
92	Exercise Benefits in Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2906-2907.	2.8	5
93	Feasibility of a Noninvasive Operability Assessment in Chronic Thromboembolic Pulmonary Hypertension under Real-World Practice. <i>Diagnostics</i> , 2020, 10, 855.	2.6	5
94	The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2021, 57, 2100115.	6.7	5
95	Pulmonary Arterial Hypertension: Epidemiology and Registries. <i>Advances in Pulmonary Hypertension</i> , 2014, 13, 21-26.	0.1	5
96	Management and prognosis of HIV-associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry. <i>Journal of Internal Medicine</i> , 2022, 292, 116-126.	6.0	5
97	Description of Two New Cases of AQP1 Related Pulmonary Arterial Hypertension and Review of the Literature. <i>Genes</i> , 2022, 13, 927.	2.4	5
98	Factores determinantes de la capacidad de ejercicio en pacientes con hipertensi3n arterial pulmonar severa. <i>Archivos De Bronconeumologia</i> , 2011, 47, 10-16.	0.8	4
99	Demythologizing pulmonary artery aneurysm: prevalence and associated complications in a large pulmonary arterial hypertension population. <i>European Heart Journal</i> , 2013, 34, P226-P226.	2.2	4
100	Fractional Flow Reserve-guided Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 863.	0.6	4
101	Hallazgo de la mutaci3n fundadora C.3344C>t(p.Pro1115Leu) en el gen EIF2KA4 en pacientes ib3ricos de etnia gitana con enfermedad veno-occlusiva pulmonar: una llamada de atenci3n a nuestra pr3ctica diaria. <i>Archivos De Bronconeumologia</i> , 2016, 52, 444-445.	0.8	4
102	Safety of Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension: Final Data Cut from the EXPERT Registry. , 2019, , .		4
103	Recent advances in the pharmacotherapy of pulmonary hypertension: practical considerations. <i>Kardiologia Polska</i> , 2021, 79, 386-392.	0.6	4
104	Sex Differences in Chronic Thromboembolic Pulmonary Hypertension. Treatment Options over Time in a National Referral Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 4251.	2.4	4
105	Pulmonary arterial hypertension. <i>Medicina Cl3nica (English Edition)</i> , 2022, 158, 622-629.	0.2	4
106	Pregnancy in Women With Structural Heart Disease: Experience in a Centre. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1189-1190.	0.6	3
107	Founder Mutation C.3344C>t(p.Pro1115Leu) in the EIF2KA4 Gene in Iberian Romani Patients With Pulmonary Venocclusive Disease: A Warning for our Daily Practice. <i>Archivos De Bronconeumologia</i> , 2016, 52, 444-445.	0.8	3
108	Comments on the 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 102-108.	0.6	3

#	ARTICLE	IF	CITATIONS
109	Left Main Extrinsic Compression in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2459-2460.	2.8	3
110	Pulmonary endarterectomy outputs in chronic thromboembolic pulmonary hypertension. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 1-8.	0.2	3
111	Soporte circulatorio con oxigenador extracorpóreo de membrana durante el embarazo en la enfermedad venooclusiva pulmonar. <i>Revista Espanola De Cardiología</i> , 2019, 72, 174-175.	1.2	3
112	Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play. <i>Archivos De Bronconeumología</i> , 2019, 55, 102-103.	0.8	3
113	From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?. <i>Advances in Therapy</i> , 2021, 38, 1860-1875.	2.9	3
114	Transition From Prostacyclin to Bosentan in Five Patients With Severe Pulmonary Hypertension: the Switch Is Possible. <i>Revista Espanola De Cardiología (English Ed)</i> , 2006, 59, 737-739.	0.6	2
115	Angioplastia pulmonar guiada por reserva de flujo fraccional en hipertensión pulmonar tromboembólica crónica. <i>Revista Espanola De Cardiología</i> , 2016, 69, 863.	1.2	2
116	Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 265-270.	0.2	2
117	Safety of Riociguat in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension with Concomitant Novel Oral Anticoagulants or Vitamin K Antagonist Use: Data from the EXPERT Registry. , 2020, , .		2
118	Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 493-504.	2.5	2
119	Selective Segmental Pulmonary Angiography: Anatomical, Technical and Safety Aspects of a Must-Learn Technique in Times of Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of Clinical Medicine</i> , 2021, 10, 3358.	2.4	2
120	El papel de la genética en la hipertensión arterial pulmonar asociada con cardiopatías congénitas. <i>Revista Espanola De Cardiología</i> , 2021, 74, 884-886.	1.2	2
121	Sildenafil como sustituto de prostaciclina subcutánea en la hipertensión pulmonar. <i>Archivos De Bronconeumología</i> , 2003, 39, 476-477.	0.8	2
122	Impact of diltiazem administration and cyclosporine levels on the incidence of acute rejection in heart transplant patients. <i>Transplant International</i> , 2003, 16, 676-680.	1.6	2
123	Long-Term Safety and Tolerability of a New Formulation of Epoprostenol in Pulmonary Arterial Hypertension (PAH) Patients: Final Results from EPITOME-2. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, S358-S359.	0.6	1
124	Surrogate Endpoints for Pulmonary Hypertension Management and Trial Design. <i>Journal of the American College of Cardiology</i> , 2018, 71, 764-765.	2.8	1
125	Extracorporeal Membrane Oxygenation Support During Pregnancy in Pulmonary Venocclusive Disease. <i>Revista Espanola De Cardiología (English Ed)</i> , 2019, 72, 174-175.	0.6	1
126	Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. <i>BMC Pulmonary Medicine</i> , 2020, 20, 154.	2.0	1

#	ARTICLE	IF	CITATIONS
127	Giant T Wave Inversion and Dyspnea in the Time of Coronavirus Pandemic. <i>Circulation</i> , 2020, 142, 906-909.	1.6	1
128	Heart Transplantation in a Distant Island Population: Accessibility and Outcomes in Patients From the Canary Islands Transplanted in Madrid. <i>Transplantation</i> , 2020, 104, 223-226.	1.0	1
129	Influence of long-standing pulmonary arterial hypertension and its severity on pulmonary artery aneurysm development. <i>Heart and Vessels</i> , 2020, 35, 1290-1298.	1.2	1
130	Selexipag Titration and Dosing Patterns in Patients with Pulmonary Arterial Hypertension (PAH) in a Real-World Clinical Setting: Insights from the EXPOSURE Study. , 2021, , .		1
131	COVID-19 Experience and Pulmonary Arterial Hypertension: Do Earlier Theses and New Data Still Match?. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1080-1081.	3.2	1
132	The role of genetics in pulmonary arterial hypertension associated with congenital heart disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 884-886.	0.6	1
133	Possible pathophysiological role of vitamin D deficit in pulmonary arterial hypertension. , 2018, , .		1
134	Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag. <i>Archivos De Bronconeumologia</i> , 2019, 55, 393-394.	0.8	1
135	Are there real differences between the treatment for young and elderly patients with chronic thromboembolic pulmonary hypertension?. <i>European Heart Journal</i> , 2020, 41, .	2.2	1
136	Early cyclosporine blood levels impact the incidence of acute rejection and overall mortality in the first year after heart transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 1671-1672.	0.6	0
137	Ilprostá" different indications and different national experiences in treating pulmonary hypertension. <i>Clinical Research in Cardiology Supplements</i> , 2010, 5, 19-23.	2.0	0
138	A Health Economic Analysis Of Sitaxentan For The Treatment Of Pulmonary Arterial Hypertension In Europe. , 2011, , .		0
139	613 Lung and Heart-Lung Transplantation in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Results from the Spanish Registry. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, S211-S212.	0.6	0
140	R�plica a la Carta al Director "Infecciones por gram negativos (BGN) en pacientes con hipertensi�n arterial pulmonar tratados con prostaciclina intravenosa". <i>Archivos De Bronconeumologia</i> , 2013, 49, 217-218.	0.8	0
141	Reply to Letter to the Editor "Infections by Gram-Negative Bacilli in Patients with Pulmonary Arterial Hypertension Treated with Intravenous Prostacyclin". <i>Archivos De Bronconeumologia</i> , 2013, 49, 217-218.	0.8	0
142	Assessment of exercise response in chronic thromboembolic pulmonary hypertension by cardiopulmonary exercise testing. <i>European Heart Journal</i> , 2013, 34, P3355-P3355.	2.2	0
143	The role of vascular obstruction site on pulsatile afterload in patients with pulmonary hypertension. <i>European Heart Journal</i> , 2013, 34, P285-P285.	2.2	0
144	Fibrosing mediastinitis, an unusual clinical entity reminding chronic thromboembolic pulmonary hypertension. <i>Medicina Cl�nica (English Edition)</i> , 2016, 147, 130-131.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Myocardial injury in severe heritable pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2017, 36, 818-820.	0.6	0
146	Respuesta. Medicina Clínica, 2017, 149, 320-321.	0.6	0
147	Hemodynamic Effects of the Oral Prostacyclin (IP) Receptor Agonist Ralinepag in Pulmonary Arterial Hypertension. Chest, 2017, 152, A738.	0.8	0
148	Role of right ventricular reverse remodeling in risk assessment of pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 182-183.	0.6	0
149	Selección de lo mejor del año 2017 en hipertensión pulmonar. Revista Espanola De Cardiologia, 2018, 71, 299-300.	1.2	0
150	Selection of the Best of 2017 in Pulmonary Hypertension. Revista Espanola De Cardiologia (English Ed), 2018, 71, 299-300.	0.6	0
151	Safety of Riociguat for the Treatment of Pulmonary Arterial Hypertension: Final Data Cut from the EXPERT Registry. , 2019, , .		0
152	Taponamiento cardiaco inverso en hipertensión pulmonar grave. Medicina Clínica, 2020, 154, 287.	0.6	0
153	CONTEMPORARY TREATMENT PATTERNS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: INSIGHT FROM THE OBSERVATIONAL EXPOSURE STUDY. Chest, 2020, 158, A2259-A2260.	0.8	0
154	Clinical Characteristics and Treatment Patterns in Patients with Pulmonary Arterial Hypertension (PAH) Initiating Selexipag in the EXPOSURE Observational Study. , 2020, , .		0
155	Characterisation of Pulmonary Arterial Hypertension (PAH) Patients Initiating a New PAH Specific Therapy in the Context of Age: Insights from EXPOSURE. Journal of Heart and Lung Transplantation, 2021, 40, S109.	0.6	0
156	Fístula entre bronquio y arteria pulmonar. Una grave complicación de la angioplastia pulmonar en la hipertensión pulmonar tromboembólica crónica. Revista Espanola De Cardiologia, 2021, 74, 548-549.	1.2	0
157	Aneurisma gigante de la arteria pulmonar en hipertensión arterial pulmonar. Archivos De Bronconeumologia, 2021, 57, 541.	0.8	0
158	Giant pulmonary artery aneurysm in pulmonary arterial hypertension. Archivos De Bronconeumologia, 2021, 57, 541.	0.8	0
159	Left Main Coronary Artery Stent Destructuring by a Pulmonary Artery Aneurysm. Cardiovascular Revascularization Medicine, 2022, 40, 246-248.	0.8	0
160	Complications associated with peripherally inserted central catheters and Hickman, in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respiratory Medicine, 2021, 189, 106649.	2.9	0
161	562 Levosimendan for acute decompensated end-stage chronic heart failure: experience in a heart transplant programme. European Journal of Heart Failure, Supplement, 2007, 6, 130-130.	0.0	0
162	Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
163	Impact of treatment strategy in survival of patients with idiopathic pulmonary arterial hypertension. Real world evidence from Spanish National Pulmonary Hypertension Registry (REHAP). , 2018, , .		0
164	Correlation between perceived quality of life among patients with Pulmonary Arterial Hypertension, the 6-minute walking test and the risk stratification. , 2019, , .		0
165	Outcome of pulmonary hypertension associated with respiratory disease. , 2019, , .		0
166	Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). , 2019, , .		0
167	FRI0242â€¦IMPACT OF PULMONARY ARTERIAL HYPERTENSION WITH OR WITHOUT INTERSTITIAL LUNG DISEASE ON SCLERODERMA: A RETROSPECTIVE COHORT STUDY FROM THE NATIONWIDE SPANISH SCLERODERMA (RESCLE) AND PULMONARY ARTERIAL HYPERTENSION (REHAP) REGISTRIES. Annals of the Rheumatic Diseases. 2020. 79. 705.2-705.	0.9	0
168	Phenotype of patients with severe pulmonary hypertension secondary to chronic obstructive pulmonary disease: A multicentre study. , 2020, , .		0
169	Time Variability of Fibrillatory Waves Energy Predicts Long-Term Outcome of Atrial Fibrillation Concomitant Surgical Ablation. , 0, , .		0
170	Catheter Ablation Outcome Prediction with Advanced Time-Frequency Features of the Fibrillatory Waves from Patients in Persistent Atrial Fibrillation. , 0, , .		0
171	Exercise capacity in patients with Pulmonary Arterial Hypertension: multicentric analysis of aerobic capacity and survival. , 2020, , .		0
172	Treatment of severe pulmonary hypertension secondary to chronic lung disease: A multicentre study. , 2020, , .		0
173	Risk status at selexipag initiation in pulmonary arterial hypertension (PAH): Insights from EXPOSURE. , 2020, , .		0
174	Atrial Fibrillation Surgical Ablation Long-term Outcome Prediction Just with One Lead of the Preoperative Surface Electrocardiogram. , 2020, , .		0
175	Novel Time-Frequency Features of the Fibrillatory Waves Improve Catheter Ablation Outcome Prediction of Persistent Atrial Fibrillation. , 2020, , .		0
176	Pretricuspid shunt and Eisenmenger syndrome: a deadly combination. European Heart Journal, 2020, 41, .	2.2	0
177	Pulmonary arterial hypertension in Spanish pediatric registry age: clinical characterization, management and survival. European Heart Journal, 2020, 41, .	2.2	0
178	Could we suspect pulmonary veno-occlusive disease with a cardiopulmonary exercise test?. European Heart Journal, 2020, 41, .	2.2	0
179	Cardiopulmonary exercise test could predict residual pulmonary hypertension after pulmonary endarterectomy. European Heart Journal, 2020, 41, .	2.2	0
180	Pulmonary hypertension and pregnancy. Is it time to reconsider recommendations in certain groups? Contemporary outcomes in a tertiary referral centre. European Heart Journal, 2020, 41, .	2.2	0

#	ARTICLE	IF	CITATIONS
181	Idiopathic pulmonary hypertension in Spanish pediatric registry: clinical characterization, management, and risk factors for survival. <i>European Heart Journal</i> , 2020, 41, .	2.2	0
182	The role of cardiopulmonary exercise test in identifying and monitoring pulmonary veno-occlusive disease. A case report. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytac138.	0.6	0
183	Transición de prostaciclina intravenosa a subcutánea en la hipertensión pulmonar. <i>Revista Espanola De Cardiologia</i> , 2003, 56, 818-821.	1.2	0